Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapies and preventative strategies for primary and recurrent Clostridium difficile
infections
Authors
Keywords
-
Journal
Annals of the New York Academy of Sciences
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-09-22
DOI
10.1111/nyas.13958
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
- (2018) L Clifford McDonald et al. CLINICAL INFECTIOUS DISEASES
- Probiotics for prevention of Clostridium difficile infection
- (2018) John P. Mills et al. CURRENT OPINION IN GASTROENTEROLOGY
- A Generalizable, Data-Driven Approach to Predict Daily Risk of Clostridium difficile Infection at Two Large Academic Health Centers
- (2018) Jeeheh Oh et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study
- (2018) Emma J. Bishop et al. INTERNAL MEDICINE JOURNAL
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
- (2018) Benoit Guery et al. LANCET INFECTIOUS DISEASES
- Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents
- (2018) H.G. Maxwell-Scott et al. MEDECINE ET MALADIES INFECTIEUSES
- The Effect of Lactoferrin and Pepsin-Treated Lactoferrin on IEC-6 Cell Damage Induced by Clostridium Difficile Toxin B
- (2018) Kosuke Otake et al. SHOCK
- Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial
- (2017) P Daley et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
- (2017) Richard J Vickers et al. LANCET INFECTIOUS DISEASES
- Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
- (2017) Mark H. Wilcox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection
- (2017) Vicente Boix et al. Open Forum Infectious Diseases
- Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
- (2017) Melanie L. Hutton et al. Scientific Reports
- Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection
- (2016) Michael Kaleko et al. ANAEROBE
- In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
- (2016) Jane Freeman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies
- (2016) Tracey Roberts et al. CLINICAL DRUG INVESTIGATION
- New and emerging therapies for Clostridium difficile infection
- (2016) Jessica Martin et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo
- (2016) K Isa et al. HUMAN & EXPERIMENTAL TOXICOLOGY
- Potential of lactoferrin to prevent antibiotic-inducedClostridium difficileinfection
- (2016) C. H. Chilton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Impact on toxin production and cell morphology inClostridium difficileby ridinilazole (SMT19969), a novel treatment forC. difficileinfection
- (2016) Eugénie Bassères et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Surotomycin versus vancomycin forClostridium difficileinfection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial
- (2016) Christine H. Lee et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection
- (2016) Sahil Khanna et al. JOURNAL OF INFECTIOUS DISEASES
- Production and Characterization of Chemically Inactivated Genetically Engineered Clostridium difficile Toxoids
- (2016) Eugene Vidunas et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Breakthroughs in the treatment and prevention of Clostridium difficile infection
- (2016) Larry K. Kociolek et al. Nature Reviews Gastroenterology & Hepatology
- Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers
- (2016) Nicole Bézay et al. VACCINE
- Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial
- (2016) Guy de Bruyn et al. VACCINE
- Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects
- (2016) Stefano Di Bella et al. Toxins
- Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine
- (2016) Casey M. Theriot et al. mSphere
- Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection
- (2015) Thomas Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate
- (2015) Joseph M. Sturino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficile
- (2015) Mohammed Zahidul Alam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ambush of Clostridium difficile Spores by Ramoplanin: Activity in anIn VitroModel
- (2015) Carl N. Kraus et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
- (2015) Richard Vickers et al. BMC INFECTIOUS DISEASES
- A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)
- (2015) Pierre-Jean Maziade et al. CLINICAL INFECTIOUS DISEASES
- Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study
- (2015) Robert Orenstein et al. CLINICAL INFECTIOUS DISEASES
- Clostridium difficileRibotype 027: Relationship to Age, Detectability of Toxins A or B in Stool With Rapid Testing, Severe Infection, and Mortality
- (2015) Krishna Rao et al. CLINICAL INFECTIOUS DISEASES
- Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle
- (2015) A. Dalhoff et al. CLINICAL MICROBIOLOGY AND INFECTION
- Recurrent Clostridium difficile infection is associated with increased mortality
- (2015) M.A. Olsen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis
- (2015) Abhishek Deshpande et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection
- (2015) Martine Gehin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Nonclinical Safety Assessment of SYN-004
- (2015) John F. Kokai-Kun et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- Diagnosis and Treatment ofClostridium difficilein Adults
- (2015) Natasha Bagdasarian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Administration of Spores of NontoxigenicClostridium difficileStrain M3 for Prevention of RecurrentC difficileInfection
- (2015) Dale N. Gerding et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Burden of Clostridium difficile Infection in the United States
- (2015) Fernanda C. Lessa et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins
- (2015) Shuyi Chen et al. Toxins
- In vitro activity of MCB3681 against Clostridium difficile strains
- (2014) Mamun-Ur Rashid et al. ANAEROBE
- Multicenter, Randomized Clinical Trial To Compare the Safety and Efficacy of LFF571 and Vancomycin for Clostridium difficile Infections
- (2014) Kathleen Mullane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of LFF571 and Vancomycin in Patients with Moderate Clostridium difficile Infections
- (2014) Suraj G. Bhansali et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
- (2014) Marya D Zilberberg et al. BMC INFECTIOUS DISEASES
- Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
- (2014) Stuart Johnson et al. CLINICAL INFECTIOUS DISEASES
- Ecological impact of MCB3837 on the normal human microbiota
- (2014) Mamun-Ur Rashid et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
- (2014) Colin Hill et al. Nature Reviews Gastroenterology & Hepatology
- Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review
- (2014) Claire Nour Abou Chakra et al. PLoS One
- Clostridium difficile spore biology: sporulation, germination, and spore structural proteins
- (2014) Daniel Paredes-Sabja et al. TRENDS IN MICROBIOLOGY
- Clostridium difficileinfection: current, forgotten and emerging treatment options
- (2014) Dimitri M Drekonja Journal of Comparative Effectiveness Research
- Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies
- (2014) M. M. Soriano et al. Open Forum Infectious Diseases
- Investigations of the Mode of Action and Resistance Development of Cadazolid, a New Antibiotic for Treatment of Clostridium difficile Infections
- (2013) Hans H. Locher et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Is Fidaxomicin Worth the Cost? An Economic Analysis
- (2013) Sarah M. Bartsch et al. CLINICAL INFECTIOUS DISEASES
- Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection
- (2013) J. H. Boone et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses
- (2013) D. Baldoni et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis
- (2013) Claudia Slimings et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial
- (2013) C.P. Selinger et al. JOURNAL OF HOSPITAL INFECTION
- Intestinal Epithelial Restitution After TcdB Challenge and Recovery From Clostridium difficile Infection in Mice With Alanyl-Glutamine Treatment
- (2013) Raphael S. Rodrigues et al. JOURNAL OF INFECTIOUS DISEASES
- A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile
- (2013) R. G. K. Donald et al. MICROBIOLOGY-SGM
- Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study
- (2013) Arthur C. Ouwehand et al. VACCINE
- Health Care–Associated Infections
- (2013) Eyal Zimlichman et al. JAMA Internal Medicine
- Rifaximin in the treatment of recurrentClostridium difficileinfection
- (2012) E. Mattila et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Evaluation of an Oral Suspension of VP20621, Spores of Nontoxigenic Clostridium difficile Strain M3, in Healthy Subjects
- (2012) Stephen A. Villano et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanism of Action of and Mechanism of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compound LFF571
- (2012) J. A. Leeds et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of adenosine A2A receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice
- (2012) Cirle Alcantara Warren et al. BMC INFECTIOUS DISEASES
- Aktuelle Daten und Trends zur Antibiotikaresistenzentwicklung von Clostridium difficile
- (2012) L. von Müller et al. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz
- Fidaxomicin "Chaser" Regimen Following Vancomycin for Patients With Multiple Clostridium difficile Recurrences
- (2012) S. Johnson et al. CLINICAL INFECTIOUS DISEASES
- Immunisation of mares with binding domains of toxins A and B ofClostridium difficileelicits serum and colostral antibodies that block toxin binding
- (2012) S. Artiushin et al. EQUINE VETERINARY JOURNAL
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine
- (2012) Richard N. Greenberg et al. VACCINE
- Glutamine and Alanyl-Glutamine Increase RhoA Expression and ReduceClostridium difficileToxin-A-Induced Intestinal Epithelial Cell Damage
- (2012) Ana A. Q. A. Santos et al. Biomed Research International
- A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection
- (2011) K. W. Garey et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis
- (2011) Efthimia Tasina et al. LANCET INFECTIOUS DISEASES
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dose–Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients
- (2010) Xing Wang Gao et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
- (2010) Stuart H. Cohen et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with Rifaximin immediately post-vancomycin treatment
- (2009) Stuart Johnson et al. ANAEROBE
- Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe RefractoryClostridium difficileInfection
- (2009) Bjorn L. Herpers et al. CLINICAL INFECTIOUS DISEASES
- Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study
- (2009) Daniel M. Musher et al. CLINICAL INFECTIOUS DISEASES
- High Frequency of Rifampin Resistance Identified in an EpidemicClostridium difficileClone from a Large Teaching Hospital
- (2009) Scott R. Curry et al. CLINICAL INFECTIOUS DISEASES
- Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria
- (2009) D. M. Citron et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
- (2009) U. A. Ochsner et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Historical Perspectives on Studies ofClostridium difficileandC. difficileInfection
- (2008) John G. Bartlett CLINICAL INFECTIOUS DISEASES
- Chenodeoxycholate Is an Inhibitor ofClostridium difficileSpore Germination
- (2008) Joseph A. Sorg et al. JOURNAL OF BACTERIOLOGY
- Bile Salts and Glycine as Cogerminants for Clostridium difficile Spores
- (2008) J. A. Sorg et al. JOURNAL OF BACTERIOLOGY
- Decreased Diversity of the Fecal Microbiome in RecurrentClostridium difficile–Associated Diarrhea
- (2008) Ju Young Chang et al. JOURNAL OF INFECTIOUS DISEASES
- Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls
- (2008) K. Sanchez-Hurtado et al. JOURNAL OF MEDICAL MICROBIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started